Loading clinical trials...
Loading clinical trials...
Effects of Simvastatin and Rosiglitazone Combination in Patients With the Metabolic Syndrome.
The purpose of this research study is to examine if a combination of a cholesterol lowering-drug, simvastatin, with a sugar-lowering drug called rosiglitazone is more effective in improving vascular inflammation (irritation of the vessels that transport your blood) and other cardiovascular risk factors than the taking of simvastatin alone.
Age 21-75 years Metabolic syndrome (must have 3 of the 5 components) elevated waist circumference \>40inches in men, \>35 inches in women elevated triglycerides \>150mg/dL reduced HDL \<40mg/dL in men\<50 in women elevated blood pressure \>130mmHg systolic, or \>85mmHg diastolic elevated fasting glucose \>100mg/dL
Age
21 - 75 years
Sex
ALL
Healthy Volunteers
Yes
University of Chicago
Chicago, Illinois, United States
Start Date
September 1, 2006
Primary Completion Date
March 1, 2011
Completion Date
April 1, 2011
Last Updated
February 10, 2017
53
ACTUAL participants
Rosiglitazone
DRUG
Placebo Rosiglitazone
DRUG
Simvastatin
DRUG
Lead Sponsor
University of Chicago
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05041491